ClinicalTrials.gg
Drug

HMPL-013 clinical trials

Also written Fruquintinib, HMPL-013 and Fruzaqla.

studies test it
120
open now
61
in phase 3
12
first study started
2011

How each study uses HMPL-013 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the HMPL-013 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
8 Nov 2023 · FRUZAQLA · NDA 217564 (FDA, Drugs@FDA)
European Union
20 Jun 2024 · Fruzaqla · EMEA/H/C/005979 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Elunate
4
Fruquintinib Combined With Chemotherapy
2
F
2

Brand

Fruzaqla
5

Development codes

HMPL-013
22

Other names

Fruquintinib
68

In one entry with another drug

Given together, or one or the other

Fruquintinib Plus Capecitabine
4
Serplulimab + Fruquintinib
2
fruquintinib + sintilimab + SOX
2
HMPL-013+paclitaxel
2

Studies by the year they started

120 studies that test it; most in 2022 (22)

Studies that test HMPL-013, by start year
YearStudies
20111
20122
20144
20151
20162
20172
20181
20194
20205
202113
202222
202321
20249
202519
202614

By phase

A phase 1/2 study counts in both.

Phase 1
19
Phase 2
91
Phase 3
12
Phase 4
4
No phase
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 94

Hutchison Medipharma Limited (15) · Fudan University (14) · Sun Yat-sen University (9) · Hutchmed (7) · Wuhan Union Hospital, China (3) · Federation Francophone de Cancerologie Digestive (3) · RenJi Hospital (2) · Henan Cancer Hospital (2)

Often tested with

Tested in the same studies.

Tislelizumab (15) · Sintilimab (14) · Capecitabine (7) · Serplulimab (6) · FOLFIRI-Ziv-aflibercept Regimen (5) · FOLFIRI Regimen (5) · Disitamab vedotin (3) · Camrelizumab (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

HMPL-013 is the comparator. A study of two new drugs counts under both.

  • 1Tucidinostat · Chipscreen Biosciences, Ltd. · next primary completion May 2028
  • 1Sintilimab · Chipscreen Biosciences, Ltd. · next primary completion May 2028
Reaching primary completion within a year · 16

Studies that test HMPL-013.

Studies

Open first, then newest update. How each study uses HMPL-013 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 120

See all 120 studies that test HMPL-013 →

Given beside what is tested · 29 — HMPL-013 is usual care or a partner of the new treatment

Showing 20 of 29.

As the comparator · 4 — what is tested is compared with HMPL-013

Codes

What other systems call HMPL-013 · ClinicalTrials.gg INT000075

  • MeSH (NLM) C000591844HMPL-013Confirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 49DXG3M5ZWFRUQUINTINIBConfirmed FDA, NLM

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.